The Global Competent Cells Market size is expected to reach $3.7 billion by 2031, rising at a market growth of 7.9% CAGR during the forecast period.
Rising healthcare expenditures in Asia Pacific countries fuel demand for innovative biopharmaceuticals, personalized medicine, and diagnostic tools. These cells are essential in developing these healthcare solutions, contributing to market growth. Consequently, the Asia Pacific region would acquire nearly 30% of the total market share by 2031.
Recombinant DNA technology is fundamental for cloning and expressing genes in host cells. These cells are essential for introducing recombinant DNA into bacterial cells to produce therapeutic proteins, enzymes, and vaccines. In addition, the development of personalized medicine, which tailors’ treatments based on individual genetic profiles, relies on recombinant DNA technology and these cells. Hence, the growing demand for recombinant DNA technology drives the market's growth.
Additionally, these cells are essential for introducing and expressing genes of interest to study their functions. Researchers use these cells to clone specific genes, manipulate DNA sequences, and explore gene interactions, which are fundamental in understanding biological processes and disease mechanisms. Thus, the expansion of genomic and proteomic studies is propelling the market's growth.
Moreover, the pandemic spurred heightened demand for these cells as pharmaceutical and biotech companies accelerated research and development efforts for vaccines and therapies. Also, companies in the competent cells sector adapted quickly to ensure uninterrupted supply chains, enhancing market stability and growth during the pandemic. Thus, the COVID-19 pandemic had a positive impact on the market.
However, establishing a competent cell production facility requires significant investment in specialized equipment such as bioreactors, incubators, purification systems, and sterile facilities. Moreover, scaling up production from laboratory-scale to commercial quantities can involve additional costs related to process optimization, validation, and facility expansion. Hence, high initial costs are hindering the growth of the market.
Rising healthcare expenditures in Asia Pacific countries fuel demand for innovative biopharmaceuticals, personalized medicine, and diagnostic tools. These cells are essential in developing these healthcare solutions, contributing to market growth. Consequently, the Asia Pacific region would acquire nearly 30% of the total market share by 2031.
Recombinant DNA technology is fundamental for cloning and expressing genes in host cells. These cells are essential for introducing recombinant DNA into bacterial cells to produce therapeutic proteins, enzymes, and vaccines. In addition, the development of personalized medicine, which tailors’ treatments based on individual genetic profiles, relies on recombinant DNA technology and these cells. Hence, the growing demand for recombinant DNA technology drives the market's growth.
Additionally, these cells are essential for introducing and expressing genes of interest to study their functions. Researchers use these cells to clone specific genes, manipulate DNA sequences, and explore gene interactions, which are fundamental in understanding biological processes and disease mechanisms. Thus, the expansion of genomic and proteomic studies is propelling the market's growth.
Moreover, the pandemic spurred heightened demand for these cells as pharmaceutical and biotech companies accelerated research and development efforts for vaccines and therapies. Also, companies in the competent cells sector adapted quickly to ensure uninterrupted supply chains, enhancing market stability and growth during the pandemic. Thus, the COVID-19 pandemic had a positive impact on the market.
However, establishing a competent cell production facility requires significant investment in specialized equipment such as bioreactors, incubators, purification systems, and sterile facilities. Moreover, scaling up production from laboratory-scale to commercial quantities can involve additional costs related to process optimization, validation, and facility expansion. Hence, high initial costs are hindering the growth of the market.
Driving and Restraining Factors
Drivers- Growing demand for recombinant DNA technology
- Expansion of genomic and proteomic studies
- Growth of biotechnology and pharmaceutical industries
- High initial costs
- Limited shelf life of competent cells
- Rising regenerative medicine and cell therapy
- Increasing government and private funding
- Increasing competition from alternative technologies
- Quality control and standardization issues
Type Outlook
Based on type, the market is divided into chemically competent cells, electrocompetent cells, and ultracompetent cells. The electrocompetent cells segment attained 34% revenue share in the market in 2023. Electrocompetent cells typically offer higher transformation efficiencies compared to chemically competent cells. This makes them suitable for applications that require precise control over transformation efficiency, such as gene editing, library construction, and high-throughput screening.Application Outlook
On the basis of application, the market is segmented into cloning, protein expression, mutagenesis, and others. In 2023, the protein expression segment attained a 24% revenue share in the market. These cells with high transformation efficiencies and robust protein expression capabilities are preferred for generating large quantities of recombinant proteins.
End-Use Outlook
By end-use, the market is divided into pharmaceutical & biotechnology companies, academic & research institutes, and others. The academic & research institutes segment procured a 37% revenue share in the market in 2023. These cells are fundamental tools in molecular biology research for studying gene function, protein expression, and genetic pathways. Academic institutions use these cells to conduct basic research that advances our understanding of biological processes and diseases.Regional Outlook
Region-wise, the market is analyzed across North America, Europe, Asia Pacific, and LAMEA. The North America region witnessed 35% revenue share in the market in 2023. North America hosts some of the world’s leading biotechnology and pharmaceutical companies, particularly the United States and Canada. These industries drive substantial demand for these cells for research, development, and production of biopharmaceuticals, vaccines, and therapeutic proteins.- Jun-2024: Thermo Fisher Scientific established a new manufacturing practice (cGMP) facility in Bleiswijk, Netherlands, bolstering its European clinical trial capabilities for advanced therapies. The site offers comprehensive support for cell and gene therapies, emphasizing sustainable operations towards achieving net-zero emissions by 2050.
- May-2024: Thermo Fisher Scientific launched the Applied Biosystems Axiom BloodGenomiX Array, designed for accurate blood genotyping in clinical research. This innovative platform covers over 40 genes and more than 260 antigens, detecting both HLA and HPA types with an impressive concordance rate of 99.89%.
- Dec-2022: Agilent's Resolution ctDx FIRST has received FDA approval as a companion diagnostic for KRAS G12C mutations in advanced non-small cell lung cancer (NSCLC), facilitating treatment decisions for patients eligible for KRAZATI (adagrasib). Developed with Mirati Therapeutics, this liquid biopsy NGS assay offers broad genomic profiling for NSCLC patients.
- Sep-2023: Thermo Fisher Scientific and the National Minority Quality Forum are partnering through ARC to improve access to clinical research for historically underserved communities. The collaboration aims to promote diversity in trials and facilitate equitable healthcare access initiatives.
- Sep-2023: Thermo Fisher Scientific introduces the TSX Universal Series ULT Freezers, featuring enhanced performance, energy efficiency, and adaptability across lab settings. Certified by ENERGY STAR® and designed for sustainability, these freezers support diverse scientific workflows and stringent quality standards.
List of Key Companies Profiled
- Thermo Fisher Scientific, Inc.
- Merck KGaA
- Agilent Technologies, Inc.
- Bio-Rad Laboratories, Inc.
- Promega Corporation
- New England Biolabs, Inc.
- Qiagen N.V
- Hoffmann-La Roche Ltd.
- Takara Bio Inc. (Takara Holdings Inc.)
- Lonza Group Ltd. (Capsugel)
Market Report Segmentation
By Type- Chemically Competent Cells
- Electrocompetent Cells
- Ultracompetent Cells
- Cloning
- Protein Expression
- Mutagenesis
- Others
- Pharmaceutical & Biotechnology Companies
- Academic & Research Institutes
- Others
- North America
- US
- Canada
- Mexico
- Rest of North America
- Europe
- Germany
- UK
- France
- Russia
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- South Korea
- Australia
- Malaysia
- Rest of Asia Pacific
- LAMEA
- Brazil
- Argentina
- UAE
- Saudi Arabia
- South Africa
- Nigeria
- Rest of LAMEA
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market at a Glance
Chapter 3. Market Overview
Chapter 5. Global Competent Cells Market by Type
Chapter 6. Global Competent Cells Market by Application
Chapter 7. Global Competent Cells Market by End-Use
Chapter 8. Global Competent Cells Market by Region
Chapter 9. Company Profiles
Companies Mentioned
- Thermo Fisher Scientific, Inc.
- Merck KGaA
- Agilent Technologies, Inc.
- Bio-Rad Laboratories, Inc.
- Promega Corporation
- New England Biolabs, Inc.
- Qiagen N.V
- F. Hoffmann-La Roche Ltd.
- Takara Bio Inc. (Takara Holdings Inc.)
- Lonza Group Ltd. (Capsugel)
Methodology
LOADING...
